SCHEDULE: Satterfield Boosts BioCardia Stake to 9.9%

Thomas A. Satterfield, Jr. has increased his beneficial ownership in BioCardia, Inc. to 9.9% of the common stock, including shares and exercisable warrants.

Summary

• Thomas A. Satterfield, Jr. beneficially owns 592,144 shares of BioCardia, Inc. common stock.
• This represents 9.9% of the company's outstanding common stock, based on 5,801,224 shares outstanding as of August 8, 2025.
• The beneficial ownership includes 465,997 shares of common stock and 126,147 shares issuable upon the exercise of warrants.
• Mr. Satterfield holds sole voting and dispositive power over 153,603 shares and shared voting and dispositive power over 438,541 shares.
• A blocker provision limits Mr. Satterfield's beneficial ownership to 9.99% of the common stock outstanding upon exercise of most warrants, except for 17,317 warrants.
• Without the blocker provision, Mr. Satterfield could be deemed to beneficially own 749,909 shares, representing 12.32% of the issuer's outstanding common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant investor maintains a substantial stake, which is generally a positive signal of confidence. The blocker provision is a neutral to slightly negative factor for the investor's influence but a positive for company control.

Positives

• A significant investor, Thomas A. Satterfield, Jr., maintains a substantial stake of 9.9% in BioCardia, Inc., indicating continued confidence in the company.
• The investor's potential beneficial ownership, if not for blocker provisions, would be 12.32%, suggesting a strong underlying interest in the company's equity.

Negatives

• The presence of a blocker provision limits the investor's ability to increase their beneficial ownership beyond 9.99%, potentially restricting their influence or further investment.

Risks

• The blocker provision on most warrants limits the beneficial ownership of Thomas A. Satterfield, Jr. to 9.99%, which could restrict his ability to increase his stake or exert greater influence over the company.

Future Outlook

N/A

Industry Context

N/A

Corporate Governance

Related Party Transactions

• Shares are held by entities controlled by Thomas A. Satterfield, Jr., including Tomsat Investment & Trading Co., Inc. (wholly owned), A.G. Family L.P. (managed by a general partner controlled by him), and Caldwell Mill Opportunity Fund, LLC (managed by an entity 50% owned by him, where he is Chief Investment Manager).
• Mr. Satterfield also has limited power of attorney for voting and disposition of 2,500 shares held by Rebecca A. Satterfield.

Stakeholder Impact

• Shareholders may view the continued significant stake by Thomas A. Satterfield, Jr. as a positive signal of investor confidence in BioCardia, Inc.'s long-term prospects.
• The company's management and board may feel more secure with a large, but capped, investor, as the blocker provision limits potential activist pressure from this specific shareholder.

Key Dates

Recommendation

The filing indicates a significant investor, Thomas A. Satterfield, Jr., maintains a substantial stake in BioCardia, Inc., signaling continued confidence. However, as a Schedule 13G, it primarily discloses ownership and does not provide operational or financial performance data. Therefore, while the investor's position is a positive indicator, a 'hold' recommendation is appropriate until further financial and strategic updates from the company are available to assess its fundamental performance and future prospects.

Keywords

BioCardia, BCDA, Thomas Satterfield, Schedule 13G, beneficial ownership, common stock, warrants, investment, healthcare, biotechnology